Pirtobrutinib maintenance after CAR-T for resistant blood lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a drug called pirtobrutinib can help keep your lymphoma under control after you've received CAR-T cell therapy (a type of immune cell treatment). The study wants to see if adding this maintenance drug prevents the lymphoma from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with large B-cell lymphoma (a type of blood cancer) and have already received CAR-T cell therapy
- You are 18 years or older and able to understand and sign consent forms
- You are within 28 days after your CAR-T infusion
- Any side effects from previous cancer treatments have gotten better (Grade 1 or mild)
- You have a good overall health status and can do light to moderate activities
- You do not have other active cancers, serious infections, or immune system disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a daily pill called zanubrutinib after CAR-T cell therapy can help keep your lymphoma from coming back. If you have non-Hodgkin B-cell lymphoma and you are about to start or are already taking zanubrutinib after CAR-T treatment, you may be eligible.
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
This study tests pirtobrutinib, a new drug similar to ones you may have already tried, in patients whose B-cell lymphoma (a blood cancer) stopped responding to or caused side effects from prior BTK inhibitor treatments. The goal is to see if this different drug works better for people in your situation.
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.